ClinicalTrials.gg

Polycythemia Vera clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 278 studies for Polycythemia Vera across more than 10 countries. 53 are recruiting or about to start. 106 of them are mainly about Polycythemia Vera (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
147
Recruiting
42
Terminated
32
Active, not recruiting
19
Withdrawn
14
Status unknown
12

Phase

Phase 2
121
Phase 1
72
Phase 3
35
Phase 4
3
Early Phase 1
3

Where

United States
179
Italy
44
France
38
Germany
33
United Kingdom
27
Canada
24

Who develops what

Add Polycythemia Vera to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 12 companies, 12 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Chengdu Zenitar Biomedical Technology, Agios Pharmaceuticals and Incyte here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ruxolitinibRecent, limited
Evidence
  • NCT07722611 · Merck & Co., Inc · Phase 3 · live · comparator · “Ruxolitinib” · registered Jul 2026
  • NCT04354727 · Ascentage Pharma Group International · Phase 2 · background · “Ruxolitinib” · registered Apr 2020
  • NCT03669965 · Ipsen · Phase 2 · comparator · “Ruxolitinib” · registered Sep 2018
  • NCT01981850 · Hoffmann-La Roche · Phase 2 · background · “Ruxolitinib” · registered Oct 2013
  • NCT01787552 · Novartis · Phase 2 · background · “INC424” · registered Feb 2013
Incyte Corporation72% of its industry studiesUS: Incyte Corporation (FDA 2011)EU: Novartis (EMA 2012) + 1 other11 study
HydroxyureaRecent, limited
Evidence
  • NCT06093672 · Italfarmaco · Phase 3 · live · comparator · “Hydroxyurea” · registered Oct 2023
  • NCT01949805 · AOP Orphan Pharmaceuticals AG · Phase 3 · comparator · “Hydroxyurea” · registered Sep 2013
  • NCT01632904 · Incyte Corporation · Phase 3 · comparator · “Hydroxyurea (HU)” · registered Jun 2012
Norgine33% of its industry studiesUS: off-patent, 5 generics marketedEU: Norgine (EMA 2007) + 1 other11 study
ropeginterferon alfa-2bRecent, limited
Evidence
  • NCT07722611 · Merck & Co., Inc · Phase 3 · live · comparator · “Ropeginterferon alfa-2b” · registered Jul 2026
PharmaEssentia55% of its industry studiesUS: PharmaEssentia (FDA 2021)EU: AOP Orphan Pharmaceuticals AG (EMA 2019)11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
sapablursen☆ Track1 live phase-3 study: NCT07429266Ono Pharmaceutical Co. Ltd
AG-236☆ Track1 live phase-3 study: NCT07859423Agios Pharmaceuticals, Inc.
bomedemstat☆ Track2 live phase-3 studies: NCT07722611, NCT06351631Merck & Co., Inc

The 3 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jul 2027 est.Anti-TMPRSS6 Monoclonal Antibody DISC-3405 · Disc Medicine, Inc · Phase 2 main aimNCT06985147 A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) — primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE · 60 enrolled
  • 30 Jul 2027 est.flonoltinib, Extended Phase Dose Group · Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 2 main aimNCT07232290 Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera — primary endpoint: The proportion of subjects who achieved HCT control · 60 enrolled
  • 28 Oct 2027 est.rusfertide · Takeda · Phase 2 main aimNCT07648030 A Study of Rusfertide in Japanese Adults With Polycythemia Vera — primary endpoint: Percentage of Participants Achieving a Response Starting at Week 20 through Week 32 · 9 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Polycythemia Vera studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · JAK inhibitors 6 open · Antimetabolites 2 open · Alkylating agents 1 open · HDAC inhibitors 1 open

Coming up

23studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stop at 75 or younger. 4 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (2%) take healthy volunteers.

Recruiting studies that take each age, of 42
AgeWomenMen
103 (7%)3 (7%)
1840 (95%)40 (95%)
3041 (98%)41 (98%)
4041 (98%)41 (98%)
5041 (98%)41 (98%)
6542 (100%)42 (100%)
7542 (100%)42 (100%)
8541 (98%)41 (98%)

Across all 278 studies, recruiting or not: 17% stop at 75 or younger and 8% at 65; 21% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Polycythemia Vera studies take

Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 281 mo40–135 · 44 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 278. Browse all 278 → or search them.